324002-53-1

Basic information

• Product Name: N-benzyl-4-(4-chlorophenyl)-4-methylpiperidine
• Synonyms: N-benzyl-4-(4-chlorophenyl)-4-methylpiperidine
• CAS NO: 324002-53-1
• Molecular Weight: 299.843
• Mol File: 324002-53-1.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: N-benzyl-4-(4-chlorophenyl)-4-methylpiperidine(CAS DataBase Reference)
• NIST Chemistry Reference: N-benzyl-4-(4-chlorophenyl)-4-methylpiperidine(324002-53-1)
• EPA Substance Registry System: N-benzyl-4-(4-chlorophenyl)-4-methylpiperidine(324002-53-1)

Safety Data

• Hazardous Substances Data: 324002-53-1(Hazardous Substances Data)

Upstream product

• 3612-20-2 1-phenylmethyl-4-piperidone 
• 3970-66-9 1-benzyl-4-methyl-piperidin-4-ol 
• 108-90-7 chlorobenzene 

Relevant articles and documents

Synthesis of 4-substituted 4-arylpiperidines

Several novel 4-substituted 4-arylpiperidines were synthesized. The chemistry leading to 4-(4-chlorophenyl)-4-fluoropiperidine (6), 4-azido-4-(4-chlorophenyl)piperidine (7) and 4-(4-chlorophenyl)-4-methylpiperidine (8) is described. (C) 2000 Elsevier Science Ltd.

(4-PHENYL-PIPERIDIN-1-YL)-[5-1H-PYRAZOL-4YL)-THIOPHEN-3-YL]-METHANONE COMPOUNDS AND THEIR USE

The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain (4-phenyl-piperidin-1-yl)- [5-(1 H-pyrazol-4-yl)-thiophen-3-yl]-methanone compounds that, inter alia, inhibit 11 β-hydroxysteroid dehydrogenase type 1 (11 β-HSD1 ). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit 1 1 β-hydroxysteroid dehydrogenase type 1; to treat disorders that are ameliorated by the inhibition of 11 β-hydroxysteroid dehydrogenase type 1; to treat the metabolic syndrome, which includes disorders such as type 2 diabetes and obesity, and associated disorders including insulin resistance, hypertension, lipid disorders and cardiovascular disorders such as ischaemic (coronary) heart disease; to treat CNS disorders such as mild cognitive impairment and early dementia, including Alzheimer's disease; etc.

Chemokine receptor antagonists and methods of use therefor

Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by: and physiologically acceptable salts thereof.